UHealth - Miller School of Medicine | Brief Strategic Family Therapy™ (BSFT™)

BSFT™ DEVELOPER TO PRESENT AT BLUEPRINTS CONFERENCE

MEET DR. SZAPOCZNIK
AT THE CONFERENCE

Consider attending the Third Annual Blueprints Conference. Participants will include community prevention advocates, department heads of agencies responsible for violence and drug prevention efforts, state and local government leaders responsible for prevention funding and initiatives, leaders of the criminal justice systems, and program implementers. To learn more about the Conference, please visit blueprintsconference.com/about/.

To learn more about BSFT™ Developer Dr. Szapocznik’s presentation Thursday morning, April 8, 2010 and the BSFT™ “Meet the Developer” hospitality suite Wednesday evening, April 7 at the Marriott Rivercenter hotel on the San Antonio River Walk, please email .(JavaScript must be enabled to view this email address).


BSFT™ Developer José Szapocznik, Ph.D.

Join BSFT™ Developer José Szapocznik, Ph.D. April 7-9, 2010 in the historic city of San Antonio, Texas for the third annual Blueprints Conference. Dr. Szapocznik who is also Professor and Chair of University of Miami's Department of Epidemiology and Public Health, will be presenting Thursday morning, April 8, 2010 the BSFT™ and hosting "Meet the Developer" hospitality suite Wednesday evening, April 7 at the Marriott Rivercenter hotel on the San Antonio River Walk. Blueprints attendees are invited to visit the BSFT™ Suite and exhibit booth, which will be open during the conference. To receive additional event details, please email .(JavaScript must be enabled to view this email address).

Dr. Szapocznik will present findings from the largest randomized clinical trial of BSFT™ conducted by the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) and implemented at community substance abuse treatment centers in seven states and the territory of Puerto Rico. The sample consisted of 1,894 individuals, including 480 families of adolescents with drug use and behavior problems. This trial, which ended in 2008, yielded a number of findings.